Fatty acid glyceride-based lipid microparticles as a long-acting injectable delivery system for brexpiprazole in schizophrenia treatment

pharmacokinetic analyses confirmed that BRE-loaded lipid microparticles (BRE-GTS) exhibited prolonged and controlled release. A single subcutaneous administration of BRE-GTS maintained therapeutic plasma levels and produced sustained antipsychotic effects for approximately two months, significantly ameliorating schizophrenia-like behaviors and improving cognitive performance. Overall, BRE-GTS represents a promising long-acting therapeutic approach for schizophrenia, combining favorable biosafety with sustained drug release, and holds substantial potential to improve medication adherence and long-term treatment outcomes.